{"id":"ff82e5a0-8955-41ed-a713-2a8984df979f","modelId":"1ede4325-d956-495d-b01b-3e5ffad096a9","versionId":null,"locationId":"404b0287-1c78-47b0-b802-f57cbcac872a","operatorId":"fffa2127-5d46-4965-b510-cf96161154f0","ownerId":null,"slug":"histosonics-edison-cleveland-ohio-usa","status":"operational","firstSeen":"2023-12-01T00:00:00.000Z","statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":["surgical_assistance"],"shiftStructure":null,"hoursPerDay":8,"siteType":"hospital","operatorConfirmed":null,"humanSupervisionOnsite":null,"locationPrecisionTier":"city_centroid","deploymentScale":"medium_11_100","siteEnvironment":"indoor","operatorType":null,"sourceQualityTier":2,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://histosonics.com/worlds-first-patients-treated-with-novel-edison-histotripsy-system/","name":"HistoSonics","title":"World's First Patients Treated With Novel Edison® Histotripsy System"}],"notes":"Cleveland Clinic treated initial patients suffering from liver tumors using the Edison histotripsy system in the same week as URMC's first treatment (December 2023). Led by Dr. C.H. David Kwon. Three patients treated initially.","keyFacts":[],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":"healthcare","scaleTier":"commercial_10_99","contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-08-08T22:32:58.082Z","updatedAt":"2026-08-21T14:24:02.943Z","model":{"id":"1ede4325-d956-495d-b01b-3e5ffad096a9","companyId":"fffa2127-5d46-4965-b510-cf96161154f0","modelName":"Edison Histotripsy System","slug":"histosonics-edison","description":"Robotic, image-guided focused ultrasound (histotripsy) platform that mechanically destroys and liquefies targeted tumors non-invasively without incisions. Uses a robotic arm to deliver focused ultrasound energy. First and only histotripsy platform cleared for clinical use globally.","formFactor":"surgical","industryVertical":"healthcare","environment":"indoor","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/our-technology/","title":"Our Technology","sourceName":"HistoSonics"},{"url":"https://histosonics.com/fda-awards-histosonics-clearance-of-its-first-of-a-kind-edison-histotripsy-system-2/","date":"2023-10-09","title":"FDA Awards HistoSonics Clearance of its Edison Histotripsy System","sourceName":"HistoSonics"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"FDA clearance","value":"De Novo 2023 (liver tumors)"},{"label":"Type","value":"Robotic histotripsy / focused ultrasound"},{"label":"Maturity","value":"Commercial / FDA-cleared"},{"label":"Applications","value":"Liver tumors (cleared), kidney (pending), pancreatic (planned)"},{"label":"Non-invasive treatment","value":"HistoSonics says the Edison Histotripsy System delivers pulsed sound energy without needles or incisions and mechanically destroys targeted liver tumors at the sub-cellular level (Our Technology)."},{"label":"Physician monitoring","value":"HistoSonics says physicians continuously monitor the treatment effect and control the Edison system in real time (Our Technology)."}],"createdAt":"2026-07-23T13:40:39.557Z","updatedAt":"2026-10-12T21:51:25.812Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":"supervised","autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"fffa2127-5d46-4965-b510-cf96161154f0","name":"HistoSonics","slug":"histosonics","description":"Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.","status":"private","founded":2009,"hq":"Plymouth, MN, USA","hqLat":45.0065149,"hqLng":-93.46651,"hqGeocodedAt":"2026-08-05T14:32:55.061Z","hqAddress":null,"hqPrecision":null,"website":"histosonics.com","fundingTotal":"102000000","type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":75,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/histosonics-secures-102m-series-d-financing/","title":"HistoSonics Secures $102M Series D Financing","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/","title":"HistoSonics stake acquired by $2B investor syndicate","sourceName":"MassDevice"},{"url":"https://www.businesswire.com/news/home/20250807749442/en/HistoSonics-Announces-%242.25B-Acquisition-by-Consortium-of-Top-Tier-Investors","title":"HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors","sourceName":"Business Wire"}],"keyFacts":[{"label":"HQ","value":"Plymouth, Minnesota, USA"},{"label":"Founded","value":"2009"},{"label":"CEO","value":"Mike Blue"},{"label":"Product","value":"Edison Histotripsy System, non-invasive focused ultrasound for tumor destruction."},{"label":"FDA","value":"De Novo authorization for liver tumors, Oct 2023; kidney indication pending."},{"label":"CE Mark (reported, Jul 2026)","value":"CE Mark granted."},{"label":"Ownership (Aug 2025)","value":"Management-led majority stake bought by K5 Global, Bezos Expeditions, Wellington; valued ~$2.25B."},{"label":"Funding (reported, unconfirmed)","value":"$102M+ Series D led by Alpha Wave Ventures."},{"label":"Valuation (reported, 2026)","value":"$3.75B"},{"label":"Investors","value":"Alpha Wave Ventures, Amzak Health, HealthQuest Capital, J&J Innovation."}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-23T13:40:08.115Z","updatedAt":"2026-10-21T00:50:33.687Z"}},"version":null,"location":{"id":"404b0287-1c78-47b0-b802-f57cbcac872a","name":"Cleveland, Ohio, USA","slug":"cleveland-ohio-usa","kind":"metro","parentLocationId":null,"region":"Midwest","lat":41.4993,"lng":-81.6944,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-08-08T22:32:50.209Z","updatedAt":"2026-08-19T19:35:53.516Z"},"operator":{"id":"fffa2127-5d46-4965-b510-cf96161154f0","name":"HistoSonics","slug":"histosonics","description":"Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.","status":"private","founded":2009,"hq":"Plymouth, MN, USA","hqLat":45.0065149,"hqLng":-93.46651,"hqGeocodedAt":"2026-08-05T14:32:55.061Z","hqAddress":null,"hqPrecision":null,"website":"histosonics.com","fundingTotal":"102000000","type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":75,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/histosonics-secures-102m-series-d-financing/","title":"HistoSonics Secures $102M Series D Financing","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/","title":"HistoSonics stake acquired by $2B investor syndicate","sourceName":"MassDevice"},{"url":"https://www.businesswire.com/news/home/20250807749442/en/HistoSonics-Announces-%242.25B-Acquisition-by-Consortium-of-Top-Tier-Investors","title":"HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors","sourceName":"Business Wire"}],"keyFacts":[{"label":"HQ","value":"Plymouth, Minnesota, USA"},{"label":"Founded","value":"2009"},{"label":"CEO","value":"Mike Blue"},{"label":"Product","value":"Edison Histotripsy System, non-invasive focused ultrasound for tumor destruction."},{"label":"FDA","value":"De Novo authorization for liver tumors, Oct 2023; kidney indication pending."},{"label":"CE Mark (reported, Jul 2026)","value":"CE Mark granted."},{"label":"Ownership (Aug 2025)","value":"Management-led majority stake bought by K5 Global, Bezos Expeditions, Wellington; valued ~$2.25B."},{"label":"Funding (reported, unconfirmed)","value":"$102M+ Series D led by Alpha Wave Ventures."},{"label":"Valuation (reported, 2026)","value":"$3.75B"},{"label":"Investors","value":"Alpha Wave Ventures, Amzak Health, HealthQuest Capital, J&J Innovation."}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-23T13:40:08.115Z","updatedAt":"2026-10-21T00:50:33.687Z"},"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/histosonics-edison-cleveland-ohio-usa","url":"https://registry.deploy.report/deployments/histosonics-edison-cleveland-ohio-usa","name":"Edison Histotripsy System at Cleveland, Ohio, USA","identifier":"ff82e5a0-8955-41ed-a713-2a8984df979f","startDate":"2023-12-01T00:00:00.000Z","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/cleveland-ohio-usa","name":"Cleveland, Ohio, USA"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/histosonics","name":"HistoSonics"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/histosonics-edison","name":"Edison Histotripsy System"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"commercial","lifecycle_state":"active","architectural_position":{"cohort":"surgical","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}